BAC
Bank of America Corporation
BAC has the edge over HNVR overall, supported by stronger valuation and stronger fundamentals.
HNVR
Hanover Bancorp, Inc.
HNVR has slightly lower modeled downside risk, despite its lower overall score.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
HNVR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
HNVR's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like HNVR.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over HNVR in the historical PE scenario, which offers more potential upside but is not a forecast.
HNVR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.7x | $9.35 | -58% |
| Forward | 7.9x | $22.23 | — |
| Fair | 11x | $16.03 | -28% |
| Current | 16x | $22.23 | — |
| Expensive | 17x | $24.34 | +9.5% |
Historical ranges are pointers, not guarantees.
HNVR's PE is in its expensive range at 16x. If earnings grow as analysts expect, today's price would be 7.9x next year's earnings, in its cheap range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
HNVR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for HNVR, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over HNVR on earnings, with more consistent year-over-year improvement.
HNVR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.81 | +101% |
| Q3 2026 | $1.40 | -7.9% |
| Q2 2026 | $1.27 | -17% |
| Q1 2026 | $1.05 | -20% |
| Q4 2025 | $1.00 | -40% |
| Q3 2025 | $1.52 | -7.9% |
| Q2 2025 | $1.53 | -7.3% |
| Q1 2025 | $1.31 | -33% |
| Q4 2024 | $1.66 | -9.8% |
HNVR's earnings per share have fallen from their peak: $1.40 over the past year, against $4.43 in mid-2022.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over HNVR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
HNVR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.3M | +7.1% |
| Q2 2026 | $19.6M | +6.6% |
| Q1 2026 | $19.1M | +4.1% |
| Q4 2025 | $18.6M | +3.3% |
| Q3 2025 | $18M | +5.6% |
| Q2 2025 | $18.4M | +8.8% |
| Q1 2025 | $18.4M | +11% |
| Q4 2024 | $18M | +13% |
HNVR's revenue has grown year over year for 11 quarters in a row: $19M last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +4.1 points |
| Q2 2026 | 28% | +9.3 points |
| Q1 2026 | 16% | +5.9 points |
| Q4 2025 | 0.7% | -28 points |
| Q3 2025 | 26% | -1.1 points |
| Q2 2025 | 18% | +12 points |
| Q1 2025 | 9.6% | -23 points |
| Q4 2024 | 29% | -2.8 points |
HNVR has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
HNVR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.7M | +504% |
| Q2 2026 | $18M | +$20.2M |
| Q1 2026 | -$2.7M | -169% |
| Q4 2025 | $8M | +278% |
| Q3 2025 | $2.4M | +18% |
| Q2 2025 | -$2.2M | +$708K |
| Q1 2025 | $3.9M | +18% |
| Q4 2024 | $2.1M | -44% |
HNVR has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over HNVR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
HNVR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -106K shares |
| 1 year | -2.3% | -165K shares |
| 3 years | -0.1% | -6.1K shares |
| 5 years | +50% | +2.4M shares |
HNVR has 7M diluted shares, down 2.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.2M |
| Q4 2025 | $1.3M |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
HNVR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 4.5x | High |
| Q1 2025 | 5.4x | High |
| Q4 2024 | 4.2x | High |
HNVR has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
HNVR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.8 | Neutral |
| Stochastic | 21.6 | Neutral |
HNVR's weekly RSI is 36 (neutral) and its Stochastic is 22 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over HNVR on valuation relative to its sector.
HNVR PE vs Financial Services Sector
| Metric | HNVR | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 13x | 22% above |
| PE % | 78 | 60 | 18 pts above |
HNVR is trading at 16x earnings, a 22% premium to the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
HNVR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.0 | 7.4% below |
| 20 week MA | $25.2 | 12% below |
| 50 week MA | $23.7 | 6.3% below |
| 100 week MA | $23.1 | 3.8% below |
| 200 week MA | $20.6 | 8% above |
HNVR has fallen below most of its moving averages, though it's still 8% above its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
HNVR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $21.5 | $19.9 | -7.8% |
| 2023 | $19.9 | $17.6 | -11% |
| 2024 | $17.6 | $22.4 | +27% |
| 2025 | $22.4 | $23.4 | +4.7% |
| 2026 YTD | $23.4 | $22.2 | -5% |
HNVR has the edge over BAC on returns for 2026, with the stronger performance.